We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAlkermes Plc

Alkermes Plc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
46.3 USD -1.59 ( 3.32%)
Last update at 2026-11-12T15:46:00Z
VOLUME
863622
Market Cap
5586.11M
P/E
23.44

Momentum Score

…

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
45.27
Low
47.00
High
52 Week Price Range
25.17
Low
36.48
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Alkermes Plc is a biopharmaceutical company developing and commercializing treatments for central nervous system disorders, with marketed therapies and a pipeline focused on long‑acting injectable and oral formulations. Long‑term growth drivers include sales from existing products, progression of late‑stage pipeline candidates, partnerships and royalty income, and international expansion, which may benefit investors seeking exposure to specialty CNS therapeutics.

Key risks are clinical and regulatory setbacks, reliance on a limited product portfolio and partner revenues, patent and litigation exposure, and pricing and reimbursement pressures that could materially affect cash flows.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
47.89
Dividend Yield
-
Revenue TTM
1475.90M
Revenue Per Share
8.96
Gross Profit TTM
1279.44M
Debt / Equity
0.04
ROE
14.72%
Net Debt
-1049.78M
ROCE
15.29%
Diluted EPS TTM
1.43

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 291.45M 443.75M 421.52M -167.30M -39.31M
Net income 241.66M 367.07M 355.76M -158.27M -48.17M
Selling general administrative 701.52M 199.02M 199.60M 605.75M 560.98M
Selling and marketing expenses - 446.21M 490.15M - -
Gross profit 1273.84M 1312.30M 1410.37M 893.69M 569.84M
Reconciled depreciation 27.16M 28.53M 74.93M 36.36M 78.65M
Ebit 303.73M 466.33M 444.55M -142.26M -26.66M
Ebitda 330.89M 494.86M 519.48M -96.15M 11.49M
Depreciation and amortization 27.16M 28.53M 74.93M 46.11M 38.15M
Non operating income net other - - - -12.00M 1.20M
Operating income 253.96M 420.64M 414.12M -142.26M -26.66M
Other operating expenses 1221.94M 1137.00M 1249.28M 1254.06M 1203.04M
Interest expense 12.28M 22.58M 23.03M 13.04M 11.22M
Tax provision 49.79M 71.61M -97.64M -9.04M 8.86M
Interest income 45.30M 42.45M 30.85M 7.63M 2.41M
Net interest income 33.03M 19.87M 7.82M -5.41M -8.81M
Income tax expense 49.79M 71.61M -97.64M -9.04M 8.86M
Total revenue 1475.90M 1557.63M 1663.40M 1111.80M 1173.75M
Total operating expenses 1019.89M 891.66M 996.25M 1035.95M 599.12M
Cost of revenue 202.06M 245.33M 253.04M 218.11M 603.91M
Total other income expense net 37.49M 23.11M 7.40M -25.04M -12.65M
Net income from continuing ops 241.66M 372.14M 519.16M -158.27M -48.17M
Net income applicable to common shares - - - -158.27M -48.17M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2530.26M 2055.57M 2136.22M 1963.98M 2024.48M
Intangible assets 83.84M 0.89M 1.99M 37.68M 74.04M
Other current assets 79.09M 91.28M 98.17M 43.53M 48.97M
Total liab 710.96M 590.59M 933.54M 920.23M 911.90M
Total stockholder equity 1819.30M 1464.98M 1202.69M 1043.75M 1112.58M
Other current liab 428.74M 412.15M 444.30M 455.08M 406.23M
Common stock 1.81M 1.77M 1.73M 1.69M 1.66M
Capital stock 1.81M 1.77M 1.73M 1.69M 1.66M
Retained earnings -734.79M -976.46M -1343.53M -1699.29M -1541.02M
Other liab - - - 42.38M 147.81M
Good will 83.84M 83.03M 83.03M 92.87M 92.87M
Other assets 936.60M - 0.00M 122.39M 224.91M
Cash 1119.78M 291.15M 457.47M 292.47M 337.54M
Total current liabilities 543.44M 465.20M 515.68M 497.74M 471.29M
Current deferred revenue - 1.25M 2.73M 6.82M 6.34M
Net debt -1049.78M -215.61M -166.74M 0.80M -41.74M
Short term debt 6.75M 6.17M 3.00M 3.00M 3.00M
Short long term debt - - 3.00M 3.00M 3.00M
Short long term debt total 70.00M 75.54M 290.73M 293.27M 295.80M
Other stockholder equity 2554.38M 2441.64M 2547.60M 2752.24M 2655.67M
Property plant equipment - - - 325.36M 341.05M
Total current assets 1929.16M 1415.36M 1431.13M 1261.92M 1291.60M
Long term investments 0.14M 73.15M 39.89M 131.61M 229.43M
Net tangible assets - - - 913.20M 945.67M
Short term investments 199.65M 460.52M 316.02M 315.99M 198.77M
Net receivables 334.02M 389.52M 333.18M 296.90M 326.56M
Long term debt - - 287.73M 290.27M 292.80M
Inventory 196.62M 182.89M 186.41M 181.42M 150.34M
Accounts payable 107.95M 45.63M 65.65M 32.84M 55.72M
Accumulated other comprehensive income -2.10M -1.97M -3.11M -10.89M -3.72M
Common stock total equity - - - 1.69M 1.66M
Retained earnings total equity - - - -1699.29M -1541.02M
Non currrent assets other 49.10M 16.50M 157.35M -1.06M -86.35M
Non current assets total 601.09M 640.21M 705.09M 702.06M 732.88M
Capital lease obligations 70.00M 75.54M 81.45M 105.55M 120.40M
Long term debt total - - - 290.27M 292.80M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 333.12M -111.31M 102.08M -28.04M -45.41M
Change to liabilities - - - 28.26M 25.52M
Total cashflows from investing activities 295.50M -111.31M 53.36M -64.54M -66.20M
Net borrowings 0.00M -291.79M -3.00M -3.00M 20.32M
Total cash from financing activities 12.38M -494.14M -289.71M -1.57M 29.07M
Change to operating activities - - - 5.64M 7.42M
Net income 241.66M 367.07M 355.76M -158.27M -48.17M
Change in cash 828.63M -166.32M 165.00M -45.07M 64.58M
Begin period cash flow 291.15M 457.47M 292.47M 337.54M 272.96M
End period cash flow 1119.78M 291.15M 457.47M 292.47M 337.54M
Total cash from operating activities 520.75M 439.12M 401.35M 21.04M 101.72M
Depreciation 27.16M 28.53M 74.93M 77.86M 78.65M
Other cashflows from investing activities 0.30M 0.46M 0.35M 1.76M 7.22M
Change to inventory -14.06M 3.09M -2.71M -31.02M -24.77M
Change to account receivables 30.17M -56.34M -44.51M 25.25M -38.01M
Sale purchase of stock -31.03M -200.28M -28.47M 19.63M 25.32M
Other cashflows from financing activities 0.01M -2.06M -275.00M 1.43M 31.32M
Change to netincome - - - 88.74M 96.78M
Capital expenditures 40.42M 33.48M 48.05M 38.26M 29.02M
Change receivables - - - 25.25M -38.01M
Cash flows other operating - - - -9.78M 11.71M
Cash and cash equivalents changes - - - -45.07M 64.58M
Change in working capital 119.12M -98.15M -36.66M 12.71M -25.55M
Stock based compensation 98.72M 96.64M 100.91M 94.25M 87.62M
Other non cash items 104.03M 4.51M 6.33M 27.28M 4.08M
Free cash flow 480.33M 405.64M 353.31M -17.21M 72.69M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ALKS
Alkermes Plc		 -1.59
3.32%		 46.30 23.44 149.25 3.78 3.13 3.50 15.63
MKKGY
Merck KGaA ADR		 -0.74
2.19%		 33.06 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -
-%		 170.05 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.34
1.66%		 21.18 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.72 - 10.66 0.01 1.16 2.94 23.11

Profile*

Alkermes Plc

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Connaught House, Dublin, Ireland, D04 C5Y6

353 1 772 8000

https://www.alkermes.com

2050

Name Title Year Born
Mr. Richard F. Pops Chairman & CEO 1962
Mr. Iain Michael Brown Sr. VP & CFO 1969
Mr. Blair C. Jackson Exec. VP & COO 1973
Mr. David Joseph Gaffin Exec. VP, Chief Legal Officer, Chief Compliance Officer & Sec. 1972
Dr. Craig C. Hopkinson M.D. Exec. VP of R&D and Chief Medical Officer 1968
Dr. Floyd E. Bloom M.D. Founder 1937
Mr. Thomas Harvey Chief Information Officer & Sr. VP of IT NA
Ms. Sandra Coombs Sr. VP of Corp. Affairs & Investor Relations NA
Mr. Michael J. Landine Sr. VP of Corp. Devel. & Chief Risk Officer 1954
Mr. Stephen Schiavo Sr. VP of HR NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…